http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102336701-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102336701-B1 |
| titleOfInvention | A pharmaceutical composition for treating cognitive decline due to stroke containing sildenafil and Rho-associasted kinase inhibitor |
| abstract | The present invention relates to a pharmaceutical composition for treating cognitive decline due to stroke, comprising sildenafil and GSK429286A. The present inventors studied to use sildenafil and a ROCK inhibitor in combination for the treatment of sequelae due to stroke based on clinical knowledge related to stroke treatment. When administered, it was confirmed for the first time that the decrease in cognitive function due to stroke is significantly improved or that cognitive function is improved compared to the normal control. It is expected to be usefully used in research related to treatment or research and cognitive function enhancement. |
| priorityDate | 2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.